| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/30/2022 | 676.57% | Cantor Fitzgerald | $15 → $14.25 | Maintains | Overweight |
| 12/20/2022 | 36.24% | Cowen & Co. | $7 → $2.5 | Downgrades | Outperform → Market Perform |
| 12/02/2022 | 145.23% | Wedbush | → $4.5 | Initiates Coverage On | → Outperform |
| 08/18/2022 | 226.98% | Piper Sandler | $9 → $6 | Maintains | Overweight |
| 08/18/2022 | 717.44% | Cantor Fitzgerald | $19 → $15 | Maintains | Overweight |
| 03/24/2022 | 390.46% | Piper Sandler | $14 → $9 | Maintains | Overweight |
| 11/15/2021 | 935.42% | Cantor Fitzgerald | $12 → $19 | Maintains | Overweight |
| 11/03/2021 | 553.95% | Cantor Fitzgerald | $12.65 → $12 | Maintains | Overweight |
| 08/05/2021 | 635.69% | Cantor Fitzgerald | $21.5 → $13.5 | Maintains | Overweight |
| 07/07/2021 | 1861.85% | Jefferies | → $36 | Initiates Coverage On | → Buy |
| 01/20/2021 | 1044.41% | Cantor Fitzgerald | $18 → $21 | Maintains | Overweight |
| 11/19/2020 | 880.93% | Cantor Fitzgerald | $16 → $18 | Maintains | Overweight |
| 10/30/2020 | 771.93% | Cantor Fitzgerald | $15 → $16 | Maintains | Overweight |
| 08/21/2020 | 717.44% | Cantor Fitzgerald | $11 → $15 | Maintains | Overweight |
| 06/12/2020 | 128.88% | Needham | → $4.2 | Initiates Coverage On | → Hold |
| 05/29/2020 | 499.46% | Cantor Fitzgerald | $9.5 → $11 | Maintains | Overweight |
| 05/27/2020 | 417.71% | Cantor Fitzgerald | $8 → $9.5 | Maintains | Overweight |
| 04/28/2020 | 335.97% | Cantor Fitzgerald | $10 → $8 | Maintains | Overweight |
| 03/30/2020 | 444.96% | Cantor Fitzgerald | $12 → $10 | Maintains | Overweight |
| 02/14/2020 | 553.95% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 09/13/2019 | 662.94% | Cowen & Co. | → $14 | Initiates Coverage On | → Outperform |
| 08/13/2019 | 499.46% | Piper Sandler | → $11 | Initiates Coverage On | → Overweight |
What is the target price for Cresco Labs (CRLBF)?
The latest price target for Cresco Labs (OTCQX: CRLBF) was reported by Cantor Fitzgerald on December 30, 2022. The analyst firm set a price target for $14.25 expecting CRLBF to rise to within 12 months (a possible 676.57% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cresco Labs (CRLBF)?
The latest analyst rating for Cresco Labs (OTCQX: CRLBF) was provided by Cantor Fitzgerald, and Cresco Labs maintained their overweight rating.
When is the next analyst rating going to be posted or updated for Cresco Labs (CRLBF)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cresco Labs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cresco Labs was filed on December 30, 2022 so you should expect the next rating to be made available sometime around December 30, 2023.
Is the Analyst Rating Cresco Labs (CRLBF) correct?
While ratings are subjective and will change, the latest Cresco Labs (CRLBF) rating was a maintained with a price target of $15.00 to $14.25. The current price Cresco Labs (CRLBF) is trading at is $1.84, which is out of the analyst's predicted range.
